Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Is Amgen Stock Outperforming the Dow?

February 25, 2026 at 07:52 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

With a market cap of $206.4 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics for serious diseases worldwide. Headquartered in Thousand Oaks, California, Amgen serves healthcare providers globally and collaborates with major biopharmaceutical partners to expand and advance its pipeline.

Companies valued at $200 billion or more are generally considered “mega-cap” stocks, and Amgen fits this criterion perfectly. Its broad portfolio includes leading treatments across inflammation, oncology, cardiovascular disease, bone health, and rare conditions, with well-known products such as Enbrel, Otezla, Prolia, Repatha, and KYPROLIS.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

Shares of Amgen have declined marginally from its 52-week high of $385.12. Over the past three months, its shares have increased 14.5%, outperforming the broader Dow Jones Industrials Average's ($DOWI) 5.9% rise during the same period.

Longer term, AMGN stock is up 23.6% over the past 52 weeks, exceeding DOWI's 13.2% gain. Moreover, shares of the company have soared nearly 17% on a YTD basis, compared to DOWI’s 2.3% return over the same time frame.

The stock has been in a bullish trend, consistently trading above its 50-day and 200-day moving averages since October 2025.

Shares of Amgen jumped 8.2% following its Q4 2025 results on Feb. 3, reporting stronger-than-expected $9.9 billion in revenue and adjusted EPS of $5.29. Investor confidence was further boosted by strong forward guidance, with 2026 adjusted EPS projected at $21.60 - $23 and full-year revenue of $37 billion - $38.4 billion, slightly ahead of Wall Street expectations. Additionally, optimism around Amgen’s obesity pipeline, particularly MariTide, in six Phase 3 trials and positioned as a less-frequent alternative to weekly GLP-1 drugs, reinforced the stock’s rally.

AMGN stock has performed weaker than its rival, Gilead Sciences, Inc. (GILD). GILD stock has climbed 20.3% YTD and 33% over the past 52 weeks.

Despite the stock’s outperformance relative to the Dow year, analysts remain cautiously optimistic about its prospects. AMGN stock has a consensus rating of “Moderate Buy” from 34 analysts in coverage, and as of writing, the stock is trading above the mean price target of $355.83.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article